These include difficulties in sampling5, high costs, tumor microenvironment heterogeneity (with PD-1/PD-L1 expression potentially lower in primary tumors than in metastatic sites6), and the inability to dynamically monitor treatment responses (since PD-1/PD-L1 expression can fluctuate over time and with different anti-tumor treatment strategies6). Here, CD274 is linked to neoplasm.